Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. Eli Lilly (NYSE: LLY) has been on fire over the past ...

Eli Lilly (LLY 1.80%) has been on fire over the past two years. ... In May, it acquired SiteOne Therapeutics, a small biotech with a promising oral non-opioid pain inhibitor in clinical trials.

Eli Lilly (NYSE: LLY) has been on fire over the past two years. ... In May, it acquired SiteOne Therapeutics, a small biotech with a promising oral non-opioid pain inhibitor in clinical trials.

The buyout of SiteOne Therapeutics cost Eli Lilly $1 billion in cash. Then on June 17, Lilly announced it would acquire Verve Therapeutics, ...

Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the ...